

NEWS RELEASE

Viopas Venture Consulting forms strategic partnership with Michele Pedrocchi, PhD

Uster/Zürich, Switzerland, March 9, 2022 – Viopas Venture Consulting, dedicated advisor to biotech, pharma and digital health companies as well as investors in the healthcare industry with focus on Switzerland, Austria and Germany, and Michele Pedrocchi, PhD, announce their strategic partnership.

"We are looking forward working with Michele as strategic partner as we continue to expand Viopas Venture Consulting's activities into the area of health technology and digital health, providing services both to companies and investors active in this rapidly growing healthcare sector," commented **Thomas Meier, PhD, Managing Partner at Viopas Venture Consulting**. "Michele's expertise in in-vitro diagnostics, digital health and personalized medicine clearly supplements our current core competence in an ideal way."

"I am excited to team up with the experts of Viopas Venture Consulting, as joining forces on a project-by-project basis we will be able to offer a more comprehensive advisory service to the entire spectrum of the life science industry," added **Michele Pedrocchi, PhD**.

About Michele Pedrocchi, PhD

Michele is a seasoned healthcare executive with over 25 years of international experience spanning in-vitro diagnostics, digital health, life sciences and personalized medicine.

During his tenure at Roche, Michele held senior leadership positions across corporate strategy, commercial and business development including serving as Global Head of Strategy and Business Development for Diagnostics. Under his leadership, the division pioneered the entry into digital health and executed more than 20 acquisitions and 500 licensing deals. Prior leadership positions held at Roche included multiple international roles where Michele served as in-country and regional general manager and built a track record of profitably growing businesses in emerging and mature markets. Moreover, he had an instrumental role in introducing patient selection through Companion Diagnostics (CDx) and establishing polymerase chain reaction (PCR) as a routine diagnostics methodology. Michele is currently an Independent Strategic Advisor and Non-Executive Director to private and public healthcare companies.

Michele received his PhD in Molecular Biology from the University of Zürich and his MS degree in Biochemistry and Cell Biology from the Federal Institute of Technology (ETH) Zürich.

About Viopas Venture Consulting (VVC)

Viopas Venture Consulting is an advisory and consultancy boutique for the life science industry and healthcare investors with focus on Switzerland, Austria and Germany. The firm's clients are Biotech, early-stage and established Pharma and Digital Health companies seeking advice in business development, corporate strategy, M&A and financing. In addition, VVC supports and consults investors interested in the healthcare industry, including family offices, high-net worth individuals and institutional investors. VVC's managing partners Thomas Meier and Simon Nebel are also partners of Board Advisors Deutschland AG. For further information, please visit www.viopasventure.ch.

Contacts Viopas Venture Consulting GmbH

www.viopasventure.ch

[LinkedIn !\[\]\(339a16584d5da0f0a3ca4e9ec17bf6a1_img.jpg\) www.linkedin.com/company/viopas-venture-consulting-gmbh/](https://www.linkedin.com/company/viopas-venture-consulting-gmbh/)

Simon Nebel, PhD, MBA
Founder, Managing Partner, CEO
simon@viopasventure.ch

Thomas Meier, PhD
Managing Partner
thomas@viopasventure.ch

Ulf Grawunder, PhD
Managing Partner
ulf@viopasventure.ch

Daniel Pajer
Managing Partner, CFO
daniel@viopasventure.ch

###